Short answer
HARROW, INC. (HROW) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Global TYRVAYA rights acquisition from Viatris, expanding Harrow’s dry-eye treatment portfolio.
HARROW, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Global TYRVAYA rights acquisition from Viatris, expanding Harrow’s dry-eye treatment portfolio
- $30 million cash due at closing, funded with cash on hand
- Up to $70 million contingent milestones tied to annual TYRVAYA net-sales thresholds
- Closing targeted for second half of 2026, subject to customary conditions
- Assets include regulatory approvals, intellectual property, technology, inventory, and related contracts
Item 7.01 · Regulation FD Disclosure
- Disclosure concerns Harrow’s planned Acquisition and associated transaction milestones
- Completion remains subject to closing conditions, creating execution and timing risk
- Purchase-price funding expected at closing, with potential contingent milestone payments
- Anticipated benefits remain uncertain; investors should monitor acquisition completion and financing updates
Item EX-99.1 · Exhibit EX-99.1
- Acquisition of global TYRVAYA rights expands Harrow’s dry-eye franchise beyond VEVYE with a complementary mechanism and drop-free delivery
- $30 million cash due at closing, plus up to $70 million in net-sales milestones
- Closing expected in second half of 2026, subject to customary conditions
- TYRVAYA already approved in U.S., China, and Taiwan, with other marketing applications pending
- Management expects the acquisition to be financially accretive shortly after closing using existing commercial infrastructure
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other HARROW, INC. 8-K filings
Get the next HROW 8-K as it lands
Follow HROW for push alerts, or ask the research agent what this filing means.